# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Malignant melanoma of skin

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 115 results.
Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Status: Recruiting
Last Changed: May 28, 2019
First Received: Dec 12, 2012
Disease(s): Cutaneous Malignant Melanoma
Intervention(s): Vitamin D, arachides oleum raffinatum
Locations: Universitair Ziekenhuis Antwerpen, Dermatology, Edegem, Belgium
UZLeuven Gasthuisberg, Leuven, Belgium
Chef de Service du Service Universitaire de Dermatologie, Liège, Belgium
Dep. of Dermatology, Medical and Health Science Center University of Debrecen, Debrecen, Hungary
Neoadjuvant Atezolizumab in Cutaneous Melanoma
Status: Not yet recruiting
Last Changed: May 07, 2020
First Received: Jul 16, 2019
Disease(s): Cutaneous Melanoma
Intervention(s): Atezolizumab
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
Status: Not yet recruiting
Last Changed: Feb 05, 2020
First Received: Feb 05, 2020
Disease(s): Cutaneous Melanoma
Intervention(s): Blood sample, Cutaneous melanoma biopsy
Locations: Dermatology department, Paris, Ile De France, France
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Status: Recruiting
Last Changed: Aug 13, 2020
First Received: Mar 04, 2019
Disease(s): Cutaneous Melanoma, Stage II
Intervention(s): Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Locations: The Angeles (Cedars-Sinai Medical Center and its Affiliates), Los Angeles, California, United States
Emory University, Atlanta, Georgia, United States
Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey, United States
Memorial Sloan Kettering, New York, New York, United States
Huntsman Cancer Institue (The University of Utah), Salt Lake City, Utah, United States
... and 9 other locations.
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Status: Recruiting
Last Changed: May 21, 2020
First Received: Nov 27, 2018
Disease(s): Melanoma, In-Transit Metastasis of Cutaneous Melanoma
Intervention(s): Polidocanol Injection
Locations: Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Status: Recruiting
Last Changed: Apr 21, 2020
First Received: Oct 31, 2013
Disease(s): Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
Intervention(s): arm 1: DC Vaccine + RT, arm 2: DC Vaccine + IFN-alfa, arm 3: both arm 1 and 2 + RT, arm 4: DC Vaccine
Locations: UO Immunoterapia e laboratorio TCS, IRST IRCCS, Meldola, FC, Italy
Advanced Melanoma in Russian Experience
Status: Recruiting
Last Changed: Oct 11, 2018
First Received: Sep 10, 2018
Disease(s): Cutaneous Melanoma, Stage IV, BRAF V600 Mutation
Locations: Moscow Regional Oncologic Dispensary, Balashikha, Russian Federation
Belgorod Oncologic Dispensary, Belgorod, Russian Federation
Republican Clinical Oncologic Dispensary, Cheboksary, Russian Federation
Kaluga Regional Clinical Oncologic Dispensary, Kaluga, Russian Federation
N.N. Blokhin National Medical Research Centre of Oncology, Moscow, Russian Federation
... and 7 other locations.
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
Status: Recruiting
Last Changed: Oct 24, 2019
First Received: Feb 18, 2019
Disease(s): Cutaneous Melanoma
Intervention(s): Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11, Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13, Decisional Regret14, Clinician Preference for Treatment
Locations: Memoral Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Status: Not yet recruiting
Last Changed: Feb 15, 2019
First Received: Feb 15, 2019
Disease(s): Cutaneous Melanoma
Intervention(s): Pembrolizumab, Talimogene Laherparepvec
Minimal SN Tumor Burden
Status: Recruiting
Last Changed: Jul 17, 2018
First Received: Sep 16, 2013
Disease(s): Cutaneous Melanoma
Locations: U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
CHRU de Lille, Lille, France
CHU de Nice - Hopital De L'Archet, Nice, France
Institut Gustave Roussy, Paris, France
Charite - Universitaetsmedizin Berlin - Campus Mitte, Berlin, Germany
... and 18 other locations.